Harmony Biosciences Holdings, Inc. 8-K

What Happened Harmony Biosciences Holdings, Inc. announced the results of its 2026 Annual Meeting of Stockholders held May 14, 2026. A quorum of 50,381,309 shares was represented. Stockholders elected four Class III directors (Geno Germano, Troy Ignelzi, Ron Philip, and Andreas Wicki, Ph.D.), ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026, and approved the company’s named executive officer compensation on a non-binding, advisory basis.

Key Details

• Total shares represented: 50,381,309 (quorum).
• Proposal 1 — Election of Class III directors (votes For / Withheld / Broker Non-Votes):
  • Geno Germano: 44,963,163 For; 1,524,142 Withheld; 3,894,004 Broker Non-Votes.
  • Troy Ignelzi: 32,813,495 For; 13,673,810 Withheld; 3,894,004 Broker Non-Votes.
  • Ron Philip: 31,826,838 For; 14,660,467 Withheld; 3,894,004 Broker Non-Votes.
  • Andreas Wicki, Ph.D.: 25,114,526 For; 21,372,779 Withheld; 3,894,004 Broker Non-Votes.
    (All four nominees were duly elected.)
• Proposal 2 — Auditor ratification: Deloitte & Touche LLP was ratified (49,385,510 For; 830,697 Against; 165,102 Abstain).
• Proposal 3 — Advisory vote on executive compensation: Approved non-bindingly (33,249,862 For; 13,042,898 Against; 194,545 Abstain; 3,894,004 Broker Non-Votes).

Why It Matters These votes finalize board composition and auditor selection for investors to consider when assessing governance and oversight at Harmony. Director vote splits—particularly for Andreas Wicki and the other nominees—give insight into shareholder sentiment and opposition levels. Ratification of Deloitte ensures continuity of the independent audit for fiscal 2026, and the advisory approval of executive pay, while non-binding, signals majority shareholder support for the company’s compensation practices.